Girija Dasmahapatra, Hiral Patel, Paul Dent, Richard I. Fisher, Jonathan Friedberg and Steven Grant The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib British Journal of Haematology 161
Article first published online: 30 JAN 2013 | DOI: 10.1111/bjh.12206
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.